Effects of ACE inhibitor therapy on quality of life in patients with heart failure

Pharmacotherapy

Volumn 18, Issue 6 I, 1998, Pages 1323-1334

  Wolfel, Eugene E ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LISINOPRIL; RAMIPRIL;

CLINICAL TRIAL; EXERCISE; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEMODYNAMIC PARAMETERS; HUMAN; QUALITY OF LIFE; REVIEW; SURVIVAL; TREATMENT OUTCOME;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CLINICAL TRIALS; ENALAPRIL; HEART DISEASES; HUMANS; LISINOPRIL; QUALITY OF LIFE; RAMIPRIL; TREATMENT OUTCOME;

EID: 0031754741     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Parmley W. Quality of life: do we know what patients want? J Am Coll Cardiol 1995;26:553-4.
2. Wachtel T, Piette J, Mor V, Stein M, Fleishman J, Carpenter C. Quality of life in persons with human immunodeficiency virus infection: measurement by the medical outcomes study instrument. Ann Intern Med 1997;116:129-37.
3. Guyatt GH. Measurement of health-related quality of life in heart failure. J Am Coll Cardiol 1993;22(suppl A):185A-91.
4. Jessup M, Brozena S. Assessment of quality of life in patients with chronic congestive heart failure. Qual Life Cardiovasc Care 1988;4:53-7.
5. Barnett DB. Assessment of quality of life. Am J Cardiol 1991;67:41C-4.
6. Testa MA, Simonson DC. Assessment of quality of life outcomes. N Engl J Med 1996;334:835-40.
7. Rector TS, Francis GS, Cohn JN. Patients' self-assessment of their congestive heart failure. 1. Patient perceived dysfunction and its poor correlation with maximal exercise tests. Heart Failure 1987;3:192-6.
8. Wilson JR, Rayos E, Yeoh TK, Gothard P, Bak K. Dissociation between exertional symptoms and circulatory function in patients with heart failure. Circulation 1995;92:47-53.
9. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525-33.
10. Wilson JR, Reichek N, Dunkman WB, Goldberg S. Effect of diuresis on the performance of the failing left ventricle in man. Am J Cardiol 1981;70:234-9.
11. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987;316:1429-35.
12. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med 1991;325:293-302.
13. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-8.
14. de Graeff PA, Kingma JH, Viersma JW, Wesseling H, Lie KI. Acute and chronic effects of ramipril and captopril in congestive heart failure. Int J Cardiol 1989;23:59-67.
15. Beermann B, Nyquist O, Hoglund C, et al. Acute haemodynamic effects and pharmacokinetics of ramipril in patients with heart failure: a placebo controlled three-dose study. Eur J Clin Pharmacol 1993;45:241-6.
16. Packer M, Lee WH, Yushak M, Medina N. Comparison of captopril and enalapril in patients with severe chronic heart failure. N Engl J Med 1986;315:847-53.
17. Kramer BL, Massie BM, Topic N. Controlled trial of captopril in chronic heart failure: a rest and exercise hemodynamic study. Circulation 1983;67:807-16.
18. Konstam V, Salem D, Pouleur H, et al. Baseline quality of life as a predictor of mortality and hospitalization in 5,025 patients with congestive heart failure. Am J Cardiol 1996;78:890-5.
19. Schron E, Gorkin L, Garg R. Evaluating quality of life in congestive heart failure: issues, progress, and recommendations. In: Kennedy GT, Crawford MH, eds. Congestive heart failure: current clinical issues. Armonk, NY: Futura, 1994:121-35.
20. Gill TM, Feinstein AR. A critical appraisal of the quality of quality-of-life measurements. JAMA 1994;272:619-26.
21. Feinstein AR, Fisher MB, Pigeon JG. Changes in dyspnea-fatigue ratings as indicators of quality of life in the treatment of congestive heart failure. Am J Cardiol 1989;64:50-5.
22. Dracup K, Walden JA, Stevenson LW, Brecht M-L. Quality of life in patients with advanced heart failure. J Heart Lung Transplant 1992;11:273-9
23. Wenger NK. Quality of life: can it and should it be assessed in patients with heart failure? Cardiology 1989;76:391-8.
24. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (CSF-36). Med Care 1992;30:473-83.
25. Kaplan RM, Anderson JP. A general health policy model: update and applications. Health Serv Res 1988;23:203-50.
26. Rector TS, Cohn JN. Assessment of patient outcome with the Minnesota living with heart failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Am Heart J 1992;124:1017-25.
27. Wiklund I, Lindvall K, Swedberg K, Zupkis RV. Self-assessment of quality of life in severe heart failure - an instrument for clinical use. Scand J Psychol 1987;28:220-5
28. Rector TS, Johnson G, Dunkman WB, et al. Evaluation by patients with heart failure of the effects of enalapril compared with hydralazine plus isosorbide dinitrate on quality of life - V-HeFT II. Circulation 1993;87(suppl VI):VI-71-7.
29. Rogers WJ, Johnstone DE, Yusuf S, et al. Quality of life among 5,025 patients with left ventricular dysfunction randomized between placebo and enalapril: the studies of left ventricular dysfunction. J Am Coll Cardiol 1994;23:393-400.
30. Gundersen T, Wiklund I, Swedberg K, et al. Effects of 12 weeks of ramipril treatment on the quality of life in patients with moderate congestive heart failure: results of a placebo-controlled trial. Cardiovasc Drugs Ther 1995;9:589-94.
31. Rector TS, Kubo SH, Cohn JN. Validity of the Minnesota living with heart failure questionnaire as a measure of therapeutic response to enalapril or placebo. Am J Cardiol 1993;71:1106-7.
32. Blackwood R, Mayow RA, Garnham JC, Armstrong C, Byrant B. Exercise capacity and quality of life in the treatment of heart failure. Clin Pharmacol Ther 1990;48:325-32.
33. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-91.
34. Ramipril B-1 Study Group. Efficacy and safety of ramipril (HOE 498) in patients with congestive heart failure in a double-blind, placebo-controlled trial. Data on file. Hoechst Marion Roussel, Inc., Somerville, NJ; August 1994.
35. Gorkin L, Norvell NK, Rosen RC, et al. Assessment of quality of life as observed from the baseline data of the studies of left ventricular dysfunction (SOLVD) trial quality-of-life substudy. Am J Cardiol 1993;71:1069-73.
36. Lewis GRJ. Lisinopril versus placebo in older congestive heart failure patients. Am J Med 1988;85(suppl 3B):48-54.
37. Beller B, Bulle T, Bourge RC, et al. Lisinopril versus placebo in the treatment of heart failure: the lisinopril heart failure study group. J Clin Pharmacol 1995;35:673-80.
38. Giles TD, Fisher MB, Rush JE. Lisinopril and captopril in the treatment of heart failure in older patients. Am J Med 1988;85(suppl 3B):44-7.
39. Giles TD, Katz R, Sullivan JM, et al. Short- and long-acting angiotensin converting enzyme inhibitors: a randomized trial of lisinopril versus captopril in the treatment of congestive heart failure. J Am Coll Cardiol 1989;13:1240-7.
40. Johnson G, Carson P, Francis GS, Cohn JN. Influence of prerandomization (baseline) variables on mortality and on the reduction of mortality by enalapril. Circulation 1993;87(suppl VI):VI-32-9.
41. Cushman DW, Wang FL, Fung WC, et al. Comparisons in vitro, ex vivo and in vivo of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE). Br J Clin Pharmacol 1989;28:115S-31.
42. Anonymous. Physicians desk reference, 51st ed. Montvale, NJ: Medical Economics Company, 1997.
43. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995;273:1450-6.